Literature DB >> 10813100

A prospective and randomized study of ovarian stimulation for ICSI with recombinant FSH versus highly purified urinary FSH.

J G Franco1, R L Baruffi, J Coelho, A L Mauri, C G Petersen, E Garbellini.   

Abstract

A prospective and randomized study of ovarian stimulation with human recombinant follicle-stimulating hormone (r-FSH; Gonal-F) versus highly purified urinary FSH (u-FSH-HP; Metrodin-HP) was conducted on patients submitted to an intracytoplasmic sperm injection (ICSI) program. A total of 120 patients aged 37 years or less were stimulated in a randomized manner with r-FSH (group I = 60 patients) or u-FSH-HP (group II = 60 patients). All received a fixed dose of FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response. Human chorionic gonadotropin (hCG) at the dose of 5000 IU to 10,000 IU was administered to both groups when at least one follicle presented a diameter > or = 17 mm. The ovarian response did not differ significantly between groups I and II in terms of number of follicles > or = 16 mm (group I = 6.2 +/- 3.2; group II = 6.7 +/- 2.9; p = 0.26), number of oocytes collected (group I = 10.7 +/- 6.8; group II = 10.5 +/- 5.7; p = 0.91), number of oocytes in metaphase II (group I = 9.2 +/- 5.8; group II = 8.2 +/- 4.8; p = 0.56) or number of immature oocytes (group I = 1.8 +/- 0.9; group II = 1.9 +/- 1.7; p = 0.62). The normal fertilization rate after ICSI did not differ significantly between treatments (group I = 69.4 +/- 25; group II = 66.5 +/- 23; p = 0.38). No cases of cancellation of ovarian stimulation or of severe ovarian hyperstimulation syndrome occurred in either group. The total number of embryos obtained from patients who used r-FSH (group I = 6.3 +/- 4.5) was similar (p = 0.46) to the number obtained from patients who used u-FSH-HP (group II = 5.5 +/- 3.7), as also was the number of transferred embryos (group I = 2.8 +/- 0.8; group II = 2.6 +/- 0.9; p = 0.27). Implantation rate (26.1%) and clinical pregnancy rates per puncture (36.7%) and per embryo transfer (37.9%) were higher in patients who used r-FSH than in patients who used u-FSH-HP (19.5%, 31.7% and 32.2%, respectively), but the differences were not statistically significant. The abortion rate (p = 0.32) did not differ between groups (group I = 4.5%, n = 1 versus group II = 15.7%, n = 3). Thus far, the data do not demonstrate significant differences in ovary stimulation with r-FSH versus u-FSH in patients whose indication for assisted reproduction was the male factor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813100     DOI: 10.3109/09513590009167653

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program.

Authors:  J G Franco; R L Baruffi; A L Mauri; C G Petersen; J E Chufallo; V Felipe; E Garbellini
Journal:  J Assist Reprod Genet       Date:  2001-11       Impact factor: 3.412

2.  Comparison of the cryopreservation of human embryos obtained after intracytoplasmic sperm injection with a slow cooling or an ultrarapid cooling procedure.

Authors:  A L Mauri; C G Petersen; R L Baruffi; R C Ferreira; J G Franco
Journal:  J Assist Reprod Genet       Date:  2001-05       Impact factor: 3.412

3.  A prospective, randomized comparison of two commercial media for ICSI and embryo culture.

Authors:  A L Mauri; C G Petersen; R L Baruffi; J G Franco
Journal:  J Assist Reprod Genet       Date:  2001-07       Impact factor: 3.412

Review 4.  Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis.

Authors:  E M Bordewijk; F Mol; F van der Veen; M Van Wely
Journal:  Hum Reprod Open       Date:  2019-06-01

5.  Comparing a biosimilar follitropin alfa (Cinnal-fⓇ) with Gonal-fⓇ in women undergoing ovarian stimulation: An RCT.

Authors:  Batool Hossein Rashidi; Khashayar Sayyari; Ramin Heshmat; Saeid Amanpour; Ensieh Shahrokh Tehraninejad; Masoumeh Masoumi; Farhang Rezaei
Journal:  Int J Reprod Biomed       Date:  2021-12-13

6.  Highly purified human-derived follicle-stimulating hormone (Bravelle) has equivalent efficacy to follitropin-beta (Follistim) in infertile women undergoing in vitro fertilization.

Authors:  Richard P Dickey; John E Nichols; Michael P Steinkampf; Benjamin Gocial; Melvin Thornton; Bobby W Webster; Sandra M Bello; Jack Crain; Dennis C Marshall
Journal:  Reprod Biol Endocrinol       Date:  2003-10-03       Impact factor: 5.211

7.  The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.

Authors:  Erica Velthuis; Julie Hubbard; Salvatore Longobardi; Thomas D'Hooghe
Journal:  Adv Ther       Date:  2020-10-15       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.